Director Anthony Gibney Acquires 100,000 Shares of Clearside Biomedical Inc (CLSD)

Director Anthony Gibney has recently increased his stake in Clearside Biomedical Inc (CLSD, Financial) by purchasing 100,000 shares of the company’s stock, according to a SEC Filing dated April 18, 2024.
Clearside Biomedical Inc is a biopharmaceutical company engaged in the development of treatments that restore and preserve vision for people with serious eye diseases. The insider’s recent transaction adds to the company’s insider activity, where over the past year, there have been 6 insider buys and 2 insider sells.
On the day of the insider’s purchase, shares of Clearside Biomedical Inc were trading at $1.3, resulting in a market cap of $99.380 million.
The stock’s price-to-GF-Value ratio stands at 0.4, with a GuruFocus Value of $3.27, indicating that the stock is currently categorized as “Possible Value Trap, Think Twice” based on its GF Value.
The GF Value is determined by considering historical trading multiples, a GuruFocus adjustment factor based on the company’s historical performance, and future business performance estimates provided by Morningstar analysts.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.